HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - HeartFlow is a software company that utilizes AI for the diagnosis, treatment, and management of coronary artery disease [2] - The company was founded in 2010 and received its first FDA clearance in 2014 [2] Market Overview - HeartFlow targets the symptomatic market for coronary artery disease, estimating a total addressable market (TAM) of $5 billion [3] - As of 2025, HeartFlow has established an installed base of 1,465 accounts in the U.S., defined as hospitals or clinics with coronary CCTA imaging capabilities [3]